Sentagliptin Phosphate - single dose — Competitive Intelligence Brief

Sentagliptin Phosphate - single dose (Sentagliptin Phosphate - single dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 Diabetes Small molecule

Target snapshot

Sentagliptin Phosphate - single dose (Sentagliptin Phosphate - single dose) — Second Affiliated Hospital of Soochow University. Sentagliptin phosphate is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sentagliptin Phosphate - single dose TARGET	Sentagliptin Phosphate - single dose	Second Affiliated Hospital of Soochow University	phase 3	DPP-4 inhibitor	DPP-4
Teneli (Teneligliptin)	Teneli (Teneligliptin)	Tanabe Pharma Corporation	marketed	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)
Metformin plus vildagliptin	Metformin plus vildagliptin	Sheba Medical Center	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
CSII followed by Lina+MET	CSII followed by Lina+MET	Sun Yat-sen University	marketed	Insulin therapy combined with DPP-4 inhibitor and biguanide	Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)
Metformin / alogliptin Oral Product	Metformin / alogliptin Oral Product	University of Catanzaro	marketed	Biguanide / DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4)
alogliptin + pioglitazone	alogliptin + pioglitazone	Kun-Ho Yoon	marketed	DPP-4 inhibitor + thiazolidinedione	DPP-4 and PPAR-γ
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class